Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS)
Conditions
Keywords
Phase Ib, BHLRM, AML, MDS, HDM201, TP53, MBG453, TIM-3, venetoclax, Bcl-2
Brief summary
This was a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or venetoclax in subjects with AML or high-risk MDS. For all subjects, TP53wt status had to be characterized by, at a minimum, no mutations noted in exons 5, 6, 7 and 8. Two treatment arms enrolled subjects in parallel to characterize the safety, tolerability, PK, PD and preliminary antitumor activity of HDM201+MBG453 (treatment arm 1) and HDM201+venetoclax (treatment arm 2). * In the treatment arm 1, subjects received HDM201 in combination with MBG453. * In the treatment arm 2, subjects received HDM201 in combination with venetoclax. Venetoclax dose was gradually increased (ramp-up) over a period of 4 to 5 days to achieve the daily target dose tested that was subsequently continued. Upon the completion of the escalation part, MTD(s) and/or RD(s) of HDM201 in combination with MBG453 or venetoclax in AML and high-risk MDS subjects was planned to be determined for each treatment arm.
Interventions
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Main Inclusion Criteria: * Male or female patients ≥ 18 years of age at the date of ICF signature who present with one of the following: 1. Relapsed/refractory AML following ≥1 prior therapies (but ≤3 prior therapies) who have relapsed or exhibited refractory disease (primary failure) and are deemed by the Investigator not to be candidates for standard therapy, including re-induction with cytarabine or other established chemotherapy regimens for patients with AML (patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded) 2. First line AML patient unfit for standard induction chemotherapy (includes both de novo and secondary AML), except in countries where approved therapies are available. Patients who are suitable for hematopoietic stem cell transplantation and willing to receive it are excluded. 3. High-risk MDS patient (high and very high-risk groups according to rIPSS) who have failed hypomethylating agent therapy. * ECOG performance status ≤ 1 * TP53wt tumor. At minimum exons 5, 6, 7 and 8 in the TP53 gene must be sequenced and determined to contain no mutations. The TP53 status must be obtained from a bone-marrow sample, collected no longer than 3 months before signing the main ICF. * Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to the institutional guidelines and be willing to undergo a bone marrow aspirate and/or biopsy at screening, during and at the end of therapy on this study. Exceptions may be considered after documented discussion with Novartis. Main
Exclusion criteria
Patients eligible for this study must not meet any of the following criteria: * Prior combination treatment with compounds having the same mode of action: * mdm2 or mdm4 inhibitors combined with TIM-3 inhibitors (for patients enrolled in treatment arm1) * mdm2 or mdm4 inhibitors combined with Bcl-2 inhibitor (for patients enrolled in treatment arm2) * History of severe hypersensitivity reactions to any ingredient of study drug(s) and other monoclonal antibodies (mAbs) and/or their excipients. * Patients with acute promyelocytic leukemia with PML-RARA. * Allogeneic stem cell transplant (HSCT) within last 6 months and/or active GvHD requiring systemic immunosuppressive therapy. * GI disorders impacting absorption of oral HDM201 or venetoclax. * Evidence of active bleeding or bleeding diathesis or major coagulopathy (including familial). * Patients with active, known or suspected autoimmune disease (treatment arm 1 only). Other eligibility criteria apply.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety | at month 24 | Month 24 is assumed to be study end |
| Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety | at month 24 | Month 24 is assumed to be study end |
| Incidence of dose limiting toxicities (DLTs) of treatment | at day 28 | end of first cycle |
| Frequency of dose interuptions | at month 24 | Month 24 is assumed to be study end |
| Frequency of dose reductions | at month 24 | Month 24 is assumed to be study end |
| Dose intensities | at month 24 | measured in mg/ day Month 24 is assumed to be study end |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Presence of anti-MBG453 antibodies (treatment arm 1 HD201+MBG453) | at Day 1, Day 29 and at month 24 | — |
| Concentration of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) | at Day 1, Day 2, Day 5, Day 6 and Day 29 | — |
| Concentration of MBG453 (treatment arm 1 HDM201+MBG453) | at Day 1, Day 2, Day 8, Day 11, Day 15, Day 29 and at month 24 | — |
| PK parameter (AUC) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) | at month 6 | Cycle 6 |
| PK parameter (Cmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) | at month 6 | Cycle 6 |
| PK parameter (Tmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) | at month 6 | Cycle 6 |
| PK parameter (AUC) of MBG453 (treatment arm 1 HDM201+MBG453) | at month 6 | Cycle 6 |
| Concentration of venetoclax (treatment arm 2 HDM201+venetoclax) | at Day 1, Day 2, Day 3, Day 5, Day 6, Day 8, Day 9, Day 14, Day 15 and Day 29 | — |
| PK parameter (Tmax) of MBG453 (treatment arm 1 HDM201+MBG453) | at month 6 | Cycle 6 |
| PK parameter (AUC) of venetoclax (treatment arm 2 HDM201+venetoclax) | at month 6 | Cycle 6 |
| PK parameter (Cmax) of venetoclax (treatment arm 2 HDM201+venetoclax) | at month 6 | Cycle 6 |
| PK parameter (Tmax) of venetoclax (treatment arm 2 HDM201+venetoclax) | at month 6 | Cycle 6 |
| Changes from baseline in GDF-15 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) | at Day 1 and Day 2 | — |
| Changes from baseline in soluble TIM-3 (Treatment arm 1 HDM201+MBG453) | at month 6 | Cycle 6 |
| PK parameter (Cmax) of MBG453 (treatment arm 1 HDM201+MBG453) | at month 6 | Cycle 6 |
| Overall Response Rate (ORR) | at month 24 | Month 24 is assumed to be study end |
| Best Overall Response (BOR) | at month 24 | Month 24 is assumed to be study end |
| Event Free Survival (EFS) for AML (Cheson 2003) or Progression Free Survival (PFS) for MDS (Cheson 2006) | at month 24 | Month 24 is assumed to be study end |
| Relapse Free Survival (RFS) for AML (Cheson 2003) or Time To Response (TTR) for MDS (Cheson 2006) | at month 24 | Month 24 is assumed to be study end |
| Duration Of Response (DOR) for AML (Cheson 2003) and MDS (Cheson 2006) | at month 24 | Month 24 is assumed to be study end |
Countries
Australia, Finland, Germany, Italy, Singapore, Spain, United States
Outcome results
None listed